Background
==========

The last decade has seen a series of randomized controlled trials (RCTs) of pharmacological treatment which have provided a strong evidence base for the role of drug treatment in the management of chronic obstructive pulmonary disease (COPD) \[[@B1]\]. The efficacy of inhaled corticosteroid/long-acting β-agonist (ICS/LABA) combinations, including the salmeterol/fluticasone propionate combination (SFC), in COPD has been clearly shown for many clinically relevant outcomes including exacerbation frequency, rate of lung function decline and health status in patients with severe and very severe COPD (GOLD stages III and IV) \[[@B2]-[@B4]\]. To date there has been a paucity of information about the effectiveness of these agents in patients with GOLD stage II COPD, with the robustness of any clinical conclusions drawn being limited by the relatively small size of the subgroups reported \[[@B5]\].

Previous RCTs examining treatment effects with these drugs recruited patients entirely or predominantly from GOLD stages III and IV \[[@B6]-[@B9]\]. These data contributed to COPD treatment guidelines recommending the use of ICS/LABA combinations to reduce the frequency and severity of exacerbations and improving lung function and health status in patients with more severe COPD (forced expiratory volume in one second \[FEV~1~\] \< 50% predicted) and a history of exacerbations. The absence of RCT data applicable to patients with GOLD stage II COPD can now be redressed through analysis of the results in patients with milder disease in recent large trials \[[@B2],[@B10]\].

The TORCH study is the largest trial of pharmacotherapy ever undertaken in COPD. It randomized over 6000 patients, and investigated the effects of SFC, salmeterol (SAL), fluticasone propionate (FP) and placebo on mortality, lung function, exacerbations and quality of life in patients with COPD. The study included patients with a pre-bronchodilator FEV~1~of less than 60% predicted irrespective of their prior exacerbation history \[[@B11]\]. As GOLD stages of severity are defined by the post-bronchodilator FEV~1~, a substantial proportion of TORCH participants had GOLD stage II disease. The TORCH data therefore provide a unique opportunity to analyse the clinical efficacy and adverse events (AEs) profile of SFC and its components (SAL and FP) in patients at different stages of COPD. In this post-hoc analysis we have focussed on the effects of SFC on mortality, exacerbations, lung function and quality of life by GOLD stage, with particular emphasis on patients with diagnosed GOLD stage II disease.

Methods
=======

Full details of the TORCH methodology have been published previously \[[@B2],[@B11]\].

Patients
--------

Current or former smokers with at least a 10-pack-year history, aged between 40 and 80 years, with a confirmed diagnosis of COPD and pre-bronchodilator FEV~1~less than 60% of the predicted value were enrolled in the TORCH study. In addition, patients were required to show less than 10% reversibility (as a percentage of predicted FEV~1~) to 400 μg salbutamol and a FEV~1~/forced vital capacity (FVC) ratio of 0.70 or less. Patients were excluded if they had a diagnosis of asthma or other non-COPD respiratory disorder, any other condition likely to cause death within 3 years, previous lung volume reduction surgery and/or lung transplantation, a requirement for oxygen therapy for at least 12 hours per day, current use of oral corticosteroid therapy, or experienced an exacerbation requiring systemic oral corticosteroid therapy and/or hospitalization during the run-in period. All patients gave written informed consent. The study was approved by local ethics review committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

Study design
------------

The TORCH study design has been described in detail in previous publications \[[@B2],[@B11]\]. Briefly, 6112 patients at 439 centres in 42 countries were included in the efficacy analyses and 6184 patients at 444 centres were included in the safety analyses. Patients were randomized using a double-blind parallel group design to receive twice-daily administration of SAL 50 μg, FP 500 μg, SFC 50 μg/500 μg, or placebo for 3 years. The primary efficacy outcome was all-cause mortality over 3 years, regardless of whether patients withdrew from the study early. Secondary outcomes were exacerbation rate, health status, lung function and AEs while on treatment.

GOLD stage analysis
-------------------

For this post-hoc analysis, baseline post-bronchodilator FEV~1~was used to group patients into GOLD-stage categories. At baseline, the highest of three acceptable measurements of FEV~1~was recorded 30 minutes after inhalation of 400 μg salbutamol via metered-dose inhaler and Volumatic spacer (ELLIPSE at US centres). The GOLD stages are categorized as follows: stage II corresponds to post-bronchodilator FEV~1~50% to \< 80% predicted, stage III to 30% to \< 50% predicted, and stage IV to \< 30% predicted \[[@B1]\]. In this post-hoc analysis of TORCH, the GOLD stage II category included 28 patients (five, two, nine and 12 in the placebo, SAL, FP and SFC treatment arms, respectively) with a post-bronchodilator FEV~1~≥ 80% (GOLD stage I).

Statistical analysis
--------------------

Time to all-cause mortality was analyzed using the log-rank test, stratified by smoking status. Exacerbation rates were analyzed using a generalized linear model (assuming the Negative Binomial distribution, to account for patient variability), adjusted for age, gender, body mass index (BMI), baseline FEV~1~, previous exacerbations, region and smoking status. Quality of life was determined using the St George\'s Respiratory Questionnaire (SGRQ). Total SGRQ scores were analyzed as changes from baseline values using repeated measures analysis of covariance (ANCOVA), using the covariates age, gender, BMI, baseline FEV~1~, baseline SGRQ, region and smoking status. Post-bronchodilator FEV~1~was analyzed using repeated measures ANCOVA with covariates of age, gender, BMI, baseline FEV~1~, region and smoking status. The rate of decline in FEV~1~was analyzed using a random coefficients model adjusted for the same covariates, with random patient effects. AEs and serious AEs (SAEs) were coded using the Medical Dictionary for Regulatory Affairs (MedDRA, version 8.1) and summarized by treatment arm. Time to first pneumonia analyzed using the log-rank test, stratified by smoking status and was compared across treatment arms using Kaplan-Meier estimates. Pneumonia rates were expressed as per 1000 treatment years, by dividing the total number of events by the total time on treatment in years, then multiplying by 1000.

To determine whether the treatment effects were consistent across severity groups, the interaction of treatment by severity group was tested for each endpoint.

Results
=======

Demographics
------------

Baseline characteristics were similar across groups when stratified by GOLD stage (Table [1](#T1){ref-type="table"}). The main differences between the groups were that the GOLD stage IV group had a higher proportion of males (83% versus 76% and 72% in the GOLD stage III and II groups), contained more former smokers (66% versus 57% and 53% in the GOLD stage III and II groups) and experienced more exacerbations requiring oral corticosteroids or antibiotics in the year prior to the study (mean of 1.3 versus 1.0 and 0.9 in the GOLD stage III and II groups). Baseline SGRQ total scores were higher with increasing disease severity, defined spirometrically. Mean reversibility within each GOLD stage was less than 5% of the predicted FEV~1~(Table [1](#T1){ref-type="table"}). A total of 16 patients violated the entry criteria and had reversibility 10--15% (six on placebo, three on SAL, six on FP and one on SFC). Of patients categorized as GOLD stage II, most had post-bronchodilator FEV~1~at baseline of 50% to \< 60%, however there were 796 patients (37%) with FEV~1~≥ 60% (Table [2](#T2){ref-type="table"}).

###### 

Demographic and baseline characteristics by GOLD stage\*

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Variable**                                                      **Stage IV**\             **Stage III**\                   **Stage II**\            **Total population**\
                                                                    **(\< 30% predicted)**\   **(30% to \< 50% predicted)**\   **(≥ 50% predicted)**\   **(n = 6112)**
                                                                    **(n = 937)**             **(n = 3019)**                   **(n = 2156)**           
  ----------------------------------------------------------------- ------------------------- -------------------------------- ------------------------ -----------------------
  age, mean (years)                                                 64.2 ± 7.8                65.4 ± 8.1                       64.9 ± 8.7               65.0 ± 8.3

  male (%)                                                          83                        76                               72                       76

  BMI, mean (kg/m^2^)                                               23.5 ± 4.9                25.1 ± 5.0                       26.6 ± 5.2               25.4 ± 5.2

  smoking status: current (%)                                       34                        43                               47                       43

  exacerbations                                                                                                                                         

   number requiring antibiotics and/or oral corticosteroids, mean   1.3 ± 1.5                 1.0 ± 1.4                        0.9 ± 1.2                1.0 ± 1.3

   number requiring hospitalization, mean                           0.4 ± 0.7                 0.3 ± 0.7                        0.2 ± 0.5                0.2 ± 0.6

  post-bronchodilator FEV~1~, mean (ml)                             704 ± 160                 1108 ± 263                       1616 ± 399               1226 ± 443

  \% predicted post-bronchodilator FEV~1~, mean                     24.6 ± 4.0                40.1 ± 5.7                       58.8 ± 7.4               44.3 ± 13.4

  SGRQ score, mean                                                  (n = 730)                 (n = 2460)                       (n = 1761)               (n = 4951)

   total score                                                      56.5 ± 15.0               50.0 ± 16.5                      45.4 ± 17.7              49.3 ± 17.1

   symptoms score                                                   67.0 ± 18.0               63.5 ± 19.3                      60.3 ± 21.0              62.9 ± 19.9

   activity score                                                   73.4 ± 16.7               64.1 ± 19.0                      57.1 ± 20.6              63.0 ± 20.0

   impact score                                                     43.6 ± 18.6               37.7 ± 18.8                      33.6 ± 19.6              37.1 ± 19.3

  reversibility as % of predicted FEV~1~, mean                      2.5 ± 3.2                 3.6 ± 3.6                        4.3 ± 4.0                3.7 ± 3.7
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Plus-minus values are mean ± standard deviation

###### 

Post-bronchodilator FEV~1~% predicted at baseline

  ---------------------------------------------------------------------------------------------------
  **FEV~1~, % predicted, n (%)**   **placebo**\   **SAL**\     **FP**\      **SFC**\     **total**\
                                   (n = 1524)     (n = 1521)   (n = 1534)   (n = 1533)   (n = 6112)
  -------------------------------- -------------- ------------ ------------ ------------ ------------
  \< 30%                           214 (14)       260 (17)     220 (14)     243 (16)     937 (15)

  30% to \< 50%                    775 (51)       739 (49)     777 (51)     728 (47)     3019 (49)

  50% to \< 60%                    347 (23)       335 (22)     329 (21)     349 (23)     1360 (22)

  60% to \< 70%                    148 (10)       160 (11)     165 (11)     173 (11)     646 (11)

  70% to \< 80%                    35 (2)         25 (2)       34 (2)       28 (2)       122 (2)

  ≥ 80%                            5 (\< 1)       2 (\< 1)     9 (\< 1)     12 (\< 1)    28 (\< 1)
  ---------------------------------------------------------------------------------------------------

Withdrawal
----------

Increasing severity by GOLD staging was associated with a higher probability of withdrawal over the 3-year study. More patients withdrew in the placebo arm compared with the SFC arm in all severity stages, and the lowest rate of withdrawals across all treatments was in patients in GOLD stage II (Figure [1](#F1){ref-type="fig"}).

![**Rate of withdrawal of patients over the 3-years duration of the study by baseline post-bronchodilator FEV~1~% predicted**.](1465-9921-10-59-1){#F1}

Mortality
---------

In GOLD stage II, the risk of death was reduced by 33% (HR 0.67; 95% CI: 0.45, 0.98; 11.4% of the patients died on placebo compared with 7.8% on SFC). The absolute risk reduction was 3.6%. The risk of death was reduced by 5% (HR 0.95; 95% CI: 0.73, 1.24) in GOLD stage III patients and by 30% (HR 0.70; 95% CI: 0.47, 1.05) in GOLD stage IV patients (Figure [2](#F2){ref-type="fig"}).

![**All-cause mortality by baseline post-bronchodilator FEV~1~% predicted**.](1465-9921-10-59-2){#F2}

The effects of SAL and FP on the probability of death versus placebo or SFC were generally similar across GOLD stages (Figure [2](#F2){ref-type="fig"}).

Moderate/severe exacerbation rates
----------------------------------

SFC reduced the annual rate of exacerbations by 31% (CI: 19, 40) compared with placebo (mean of 0.57/year in SFC versus 0.82/year in placebo) in patients with GOLD stage II COPD. Patients with GOLD stage III and IV COPD also experienced a reduction in exacerbations. Compared with placebo, SFC reduced the number of exacerbations in patients with GOLD stage III COPD by 26% (CI: 17, 34) per year (mean of 0.91/year for SFC versus 1.24/year for placebo). In patients with GOLD stage IV COPD, SFC reduced exacerbations by 14% (CI: -4, 29) per year versus placebo (mean of 1.54/year for SFC versus 1.79/year for placebo) (Figure [3](#F3){ref-type="fig"}).

![**Exacerbation rate by baseline post-bronchodilator FEV~1~% predicted**.](1465-9921-10-59-3){#F3}

FEV~1~
------

Improvements in FEV~1~with SFC versus placebo were 101 ml (95% CI: 71, 132) in GOLD stage II patients, 82 ml (95% CI: 60, 104) in GOLD stage III patients and 96 ml (95% CI: 54, 138) in GOLD stage IV patients (Figure [4](#F4){ref-type="fig"}).

![**Adjusted mean FEV~1~over 3 years by baseline post-bronchodilator FEV~1~% predicted**.](1465-9921-10-59-4){#F4}

The reduction in the rate of decline in FEV~1~with SFC versus placebo was 16 ml/year (95% CI: 0, 32) in GOLD stage II patients, 16 ml/year (95% CI: 5, 28) in GOLD stage III patients and 11 ml/year (95% CI: -8, 30) in GOLD stage IV patients (Figure [5](#F5){ref-type="fig"}).

![**Rate of decline in FEV~1~by baseline post-bronchodilator FEV~1~% predicted**.](1465-9921-10-59-5){#F5}

Health status
-------------

The greatest improvement relative to placebo was observed in those patients with more severe disease treated with SFC (Figure [6](#F6){ref-type="fig"}). The difference in adjusted mean change in SGRQ for SFC versus placebo was -2.3 (95% CI: -4.0, -0.7) in GOLD stage II, -3.3 (95% CI: -4.7, -1.9) in GOLD stage III and -5.9 (95% CI: -8.7, -3.0) in GOLD stage IV. A numerical trend to greater improvement in SGRQ with worsening GOLD stage was noted with all active treatments, however this was not statistically significant.

![**Improvement (reduction) in SGRQ vs placebo by baseline post-bronchodilator FEV~1~% predicted**.](1465-9921-10-59-6){#F6}

Treatment interaction
---------------------

There was no evidence of a difference in treatment effect across the GOLD stages on all-cause mortality (p = 0.402 for the interaction test), exacerbations (p = 0.254), post-bronchodilator FEV~1~(p = 0.298), rate of decline in FEV~1~(p = 0.830) or SGRQ (p = 0.321).

Safety
------

Consistent with the results from the original analysis, the incidence of any AE was similar across the treatment arms, irrespective of GOLD stage. The incidence of SAEs and fatal AEs was also similar across treatment arms, and increased with increasing disease severity (Table [3](#T3){ref-type="table"}). The most frequently reported AE, irrespective of GOLD stage, was an exacerbation of COPD.

###### 

Incidence of adverse events by post bronchodilator % predicted FEV~1~\*

  -----------------------------------------------------------------------------------------
  **Variable**                        **Placebo**\   **SAL**\     **FP**\      **SFC**\
                                      (n = 1544)     (n = 1542)   (n = 1552)   (n = 1546)
  ----------------------------------- -------------- ------------ ------------ ------------
  **FEV~1~\< 30% predicted**                                                   

   n                                  215            261          223          246

   any AE, n (%)                      198 (92)       241 (92)     212 (95)     230 (93)

   serious AEs, n (%)                 108 (50)       142 (54)     129 (58)     134 (54)

   fatal AEs, n (%)                   26 (12)        35 (13)      35 (16)      25 (10)

  **FEV~1~30% to \< 50% predicted**                                            

   n                                  786            750          785          735

   any AE, n (%)                      717 (91)       669 (89)     702 (89)     664 (90)

   serious AEs, n (%)                 322 (41)       306 (41)     357 (45)     327 (44)

   fatal AEs, n (%)                   70 (9)         62 (8)       87 (11)      62 (8)

  **FEV~1~≥ 50% predicted**                                                    

   n                                  543            531          544          565

   any AE, n (%)                      470 (87)       471 (89)     481 (88)     487 (86)

   serious AEs, n (%)                 197 (36)       174 (33)     169 (31)     198 (35)

   fatal AEs, n (%)                   37 (7)         29 (5)       38 (7)       27 (5)
  -----------------------------------------------------------------------------------------

\*Safety population (n = 6184)

The incidence of pneumonia increased with disease severity, irrespective of treatment. The probability of pneumonia as an AE was increased in patients receiving ICS-containing therapy (SFC, FP) compared with those patients not receiving ICS (SAL, placebo) in all GOLD stages (Table [4](#T4){ref-type="table"}; Figure [7](#F7){ref-type="fig"}). When investigating treatment interactions for time to first pneumonia, there was no evidence of treatment differences across GOLD stages (p = 0.402).

![**Probability\* of pneumonia by 156 weeks by baseline post-bronchodilator FEV~1~% predicted**. \*Kaplan-Meier probability.](1465-9921-10-59-7){#F7}

###### 

Pneumonia adverse events by post-bronchodilator FEV~1~% predicted at baseline\*

  -----------------------------------------------------------------------------------------
                                      **Placebo**\   **SAL**\     **FP**\      **SFC**\
                                      (n = 1544)     (n = 1542)   (n = 1552)   (n = 1546)
  ----------------------------------- -------------- ------------ ------------ ------------
  **FEV~1~\< 30% predicted**                                                   

   number of patients                 215            261          223          246

   total treatment exposure (yrs)     378            511          487          546

   number of events                   28             44           55           89

   rate‡                              74             86           113          163

  **FEV~1~30% to \< 50% predicted**                                            

   number of patients                 786            750          785          735

   total treatment exposure (yrs)     1626           1686         1787         1752

   number of events                   87             90           171          156

   rate‡                              54             53           96           89

  **FEV~1~≥ 50% predicted**                                                    

   number of patients                 543            531          544          565

   total treatment exposure (yrs)     1275           1334         1281         1402

   number of events                   55             48           74           79

   rate‡                              43             36           58           56
  -----------------------------------------------------------------------------------------

\*Safety population (n = 6184)

‡Rate per thousand treatment years, calculated as (events × 1000/total treatment exposure)

Discussion
==========

Large prospective randomized clinical trials are designed to report their pre-specified outcomes in the recruited population. However, clinicians are also interested in whether treatment responses vary within specific subsets of patients which, in the case of COPD, have been defined in terms of the post-bronchodilator FEV~1~thresholds used in the GOLD guidelines. Indeed guidelines require this type of post-hoc analysis since they encourage more targeted therapy to specific patient groups. Based on the size of studies like TORCH and UPLIFT \[[@B10]\], there is reasonable power to conduct exploratory post-hoc analysis of secondary outcomes. In the case of TORCH, where approximately one-third of the TORCH study population fell into the GOLD stage II category, the present post-hoc analysis demonstrates that SFC improved SGRQ, reduced exacerbations and improved lung function when compared with placebo. SFC was also associated with reduced mortality in GOLD stage II patients, compared with placebo.

TORCH recruited patients with a history of COPD, reversibility to salbutamol of \< 10% of predicted FEV~1~and excluded patients with a diagnosis of asthma. Reversibility to bronchodilation has been shown to be variable within COPD patients and the presence or absence of reversibility on a single test is not an important criterion to predict response to ICS \[[@B12]\]. A very small number of patients in TORCH (16 patients) were protocol violators on the reversibility entry criterion.

The primary purpose of the TORCH trial was to determine whether SFC reduced all-cause mortality compared with placebo treatment (effectively regular short-acting bronchodilator therapy). As discussed elsewhere \[[@B2]\], TORCH was probably underpowered to show this difference in a 4-arm study design and so particular caution is needed when interpreting mortality data between GOLD stage subgroups in this post-hoc analysis. However, while patients showed an increased risk of dying as their baseline spirometry worsened, there was a lower mortality with SFC treatment even in those with GOLD stage II disease. Clearly this finding should be confirmed by further prospective studies.

As expected, the burden of disease increased with severity regardless of the endpoint measured (mortality, exacerbations, FEV~1~, and AEs). All subgroup analyses should be treated with caution. However, treatment to prevent exacerbations seemed just as effective whatever the GOLD stage. The exacerbation frequency on placebo was lowest in GOLD stage II, but was not negligible with a rate of 0.82 events per year. We observed the same proportionate reduction in events with SFC therapy in GOLD stage II patients suggesting that treatment would be worthwhile for these patients. Deterioration in health status was seen over 3 years in the placebo arm in patients with GOLD stages III and IV, but those in GOLD II showed a small improvement. SFC improved health status by approximately the same amount from baseline in all three GOLD stages. In patients with more severe disease, the main effect of SFC appears to be to slow the rate of progression relative to placebo. However, it is clear that patients in GOLD stage II do have better health status when treated with SFC compared with placebo, with a change of over two units in total score maintained over the 3 years of study.

The treatment effects on post-bronchodilator FEV~1~followed a similar pattern across all GOLD stages. The rate of decline in FEV~1~tended to be slightly lower in GOLD stage IV than in stage II. SFC reduced the rate of FEV~1~decline by 16 ml/year versus placebo in GOLD stage II patients versus 11 ml/year in stage IV patients which is comparable to the result reported in the overall population \[[@B13]\].

In our study, the incidence and severity of AEs was generally comparable across treatment arms, regardless of GOLD stage. Increased incidence of pneumonia has previously been reported with the use of ICS-containing therapy \[[@B2]\] and whilst this was observed, the probability of pneumonia with SFC in GOLD stage II patients was lower than that observed in the overall population. Further study is required however, to determine the exact mechanisms involved. There were too few on-treatment deaths from pneumonia to analyze these by GOLD stage.

It is important to note that, although GOLD stage II is defined by a post-bronchodilator FEV~1~\> 50% but \< 80% predicted \[[@B1]\], the upper limit for eligibility to the TORCH study was pre-bronchodilator FEV~1~\< 60% predicted; therefore most patients would be expected to fall into the more severe end of stage II COPD, which was indeed found to be the case. The majority of patients who were diagnosed with GOLD stage II COPD had a baseline post-bronchodilator FEV~1~of 50% to \< 60% (1360 patients \[64%\], while 646 patients \[30%\] had a FEV~1~60% to \< 70% and only 122 \[6%\] had a FEV~1~70% to \< 80%). This distribution appears to be similar to the FEV~1~% predicted distribution of stage II COPD patients from a 2005--2007 UK General Practice Research Database population-based cohort study \[GSK Worldwide Epidemiology (WEUSKOP2207) Final study report, May 2009. Data on file\] and the demographics of the TORCH GOLD stage II population is also similar to that of the UPLIFT clinical trial \[[@B10]\]. The majority of patients were also sufficiently symptomatic, as indicated by high baseline SGRQ total score, to have presented and been diagnosed with COPD, most likely as a result of exacerbations.

This analysis provides key information on pharmacotherapy in patients presenting with milder COPD and such data are lacking in the current literature and guidelines. Calverley and colleagues \[[@B5]\] performed a similar post-hoc analysis of the TRISTAN trial, but divided patients into FEV~1~\< 50% predicted and ≥ 50% predicted and explored treatment differences by severity as a continuous variable. Lung function was found to improve with active treatment, irrespective of FEV~1~, with greatest improvements reported for patients treated with SFC. In contrast to the findings reported here, only patients with more severe disease reported significantly reduced exacerbations; however health status and breathlessness both improved with active treatment irrespective of FEV~1~. The present findings provide further evidence that SFC can be used in patients with milder COPD.

Inevitably a post-hoc analysis of this type has limitations. The study was not designed to test for differences between GOLD stages or differences between treatment arms within GOLD stages. The numbers of patients in each stage were different and analyses of treatment subgroups within stages are underpowered. However, the size of the study ensured that the baseline characteristics of patients within each treatment arm was similar in each GOLD stage. TORCH recruited patients with a pre-bronchodilator FEV~1~of \< 60% predicted, but a substantial number of patients fell into GOLD stage II disease, being defined by spirometric severity based on the post-bronchodilator value. It is important to note that all had a clinical diagnosis of COPD and that the mean total SGRQ in stage II patients was 45, indicating that they were a symptomatic group of patients. Finally, we adopted a conservative criterion with respect to study entry based on the former European Respiratory Society reversibility criterion of a change in FEV~1~of less than 10% predicted. This is likely to have limited our ability to show changes in post-bronchodilator spirometry compared with studies where no reversibility limitation was present \[[@B8],[@B14]\]. However, this is not likely to impact on our data for health status or exacerbations, which are unrelated to reversibility status \[[@B12]\].

Conclusion
==========

Our data have clinical implications. Although patients in GOLD stage IV have worse outcomes such as health status impairment, higher exacerbation rates and mortality than did those in GOLD stage II, the latter group are not free from these important complications. Secondly, treatment is effective in GOLD stage II as well as in more severe stages of COPD. Finally, the results presented here suggest that patients with COPD may obtain important benefits from SFC combination pharmacotherapy, even at milder stages of disease.
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